RESUMEN
Tuberculosis (TB) disease continues to remain one of the global threats for mankind. Till date many antibacterial compounds have been identified to target mycobacterium tuberculosis (MTB). However, the mutating nature of the mycobacteria has always posed a challenge for designing newer drugs which can target both the non-mutating and mutating forms of TB. In this process, Mycobacterial membrane protein Large 3 (MmpL3) transporter was identified as one of the key targets for inhibiting tuberculosis. Herein we have made an effort to find potential inhibitors against MmpL3 by using a pharmacophore-based virtual screening workflow, followed by molecular docking studies and molecular dynamic simulations. Based on a set of 220 compounds showing anti-tubercular activity proposed to target MmpL3 transporter with MIC values ranging from 0.003 to 737 µM, a 5-point pharmacophore ADHHR_2 model possessing one hydrogen acceptor, one hydrogen donor, two hydrophobic groups and an aromatic ring system was generated. The model validated by enrichment study was used to screen Asinex and DrugBank database to identify a potential lead compound such as DrugBank_6059 that was found to show better binding affinity (-11.36) and hydrophobic interactions with target protein in comparison to standard drug SQ109.Communicated by Ramaswamy H. Sarma.
Asunto(s)
Mycobacterium tuberculosis , Tuberculosis , Humanos , Simulación del Acoplamiento Molecular , Proteínas de la Membrana/metabolismo , Antituberculosos/química , Farmacóforo , Mycobacterium tuberculosis/metabolismo , Tuberculosis/microbiología , Proteínas de Transporte de Membrana/metabolismo , HidrógenoRESUMEN
Snake envenomation leads to the formation of damage-associated molecular patterns (DAMPs), which are mediated by endogenous intracellular molecules. These are recognized by pattern-recognition receptors (PRRs) and can induce sterile inflammation. AIMS: In the present study, we aim at understanding the mechanisms involved in DAMPs induced sterile inflammation to unravel the novel therapeutic strategies for treating snake bites. The potential of benzodiazepinone derivatives to act against snake venom induced inflammation has been explored in the present investigation. MAIN METHODS: Three compounds VA 17, VA 43 and PA 03 were taken from our library of synthetic compounds. Oxidative stress markers such as lipid peroxidation, superoxide and nitric oxide were measured along with the analysis of DAMPs (IL6, HMGB1, vWF, S100b and HSP70). These compounds have been docked using molecular docking against the snake venom PLA2 structure (PDB code: 1OXL). KEY FINDINGS: The compounds have been found to effectively neutralize viper and cobra venoms induced lethal activity both ex vivo and in vivo. The compounds have also neutralized the viper venom induced hemorrhagic, coagulant, anticoagulant reactions as well as inflammation. The fold of protection have always been found to be higher in case of ex vivo than in in vivo. These compounds have neutralized the venom induced DAMPs as exhibited by IL6, HMGB1, vWF, S100b and HSP70. The fold of neutralization is found to be higher in VA 43. SIGNIFICANCE: The identified compounds could be used as potential candidates for developing treatment of snakebites in areas where antiserums are not yet available.
Asunto(s)
Proteína HMGB1 , Mordeduras de Serpientes , Animales , Antivenenos/química , Antivenenos/farmacología , Antivenenos/uso terapéutico , Inflamación/inducido químicamente , Inflamación/tratamiento farmacológico , Interleucina-6 , Simulación del Acoplamiento Molecular , Mordeduras de Serpientes/tratamiento farmacológico , Venenos de Víboras , Factor de von WillebrandRESUMEN
Tuberculosis (TB) caused by Mycobacterium tuberculosis (MTB) is one of the leading causes of mortality worldwide, with an estimated 1.5 million deaths annually. The majority of infection cases are reported from the Southeast Asian region, including India. After the discovery of Streptomycin in 1943 and its anti-tubercular activity in 1945, drug discovery efforts identified Isoniazid, Ethambutol, and Rifampin as TB-actives. However, over the years, these drugs have been rendered ineffective due to genetic mutations in mycobacterial strains. This has shifted drug discovery efforts towards identifying new targets and drugs for drug-resistant forms of bacteria. ATP synthase was identified as one of the key targets of MDR-TB. This review provides key insights into the ATP synthase target, structure activity relationship studies (SAR) of diarylquinoline class of inhibitors and their clinical relevance for treating MDR-TB.
Asunto(s)
Complejos de ATP Sintetasa/antagonistas & inhibidores , Antituberculosos , Diarilquinolinas/farmacología , Descubrimiento de Drogas , Tuberculosis , Adenosina Trifosfato , Antituberculosos/farmacología , Inhibidores Enzimáticos/farmacología , Humanos , Mycobacterium tuberculosis/efectos de los fármacos , Tuberculosis/tratamiento farmacológico , Tuberculosis Resistente a Múltiples Medicamentos/tratamiento farmacológicoRESUMEN
Attributed to several side effects, especially on hepatic tissues and body weight, there is always an urge of innovation and upgrading in already existing medication being used in maintaining diabetic condition. Therefore, in the present work, forty-eight molecules derived from arylpropionic acid scaffold were synthesized and their evaluation against diabetes was carried out. The synthesis of these molecules attributed to excellent dock score displayed by all the structures performed against PPAR-γ receptor site. Subsequently, all the derivatives were primarily deduced for their antidiabetic potential by OGTT. The compounds that showed significant antidiabetic activity in OGT Test and also exhibited high dock scores were assessed further by in vitro PPAR transactivation assay to assure analogy between in vivo and in vitro studies. The antidiabetic activity of these active compounds was then evaluated on STZ induced diabetic model in vivo. The most active compounds were scrutinized for its effect on PPAR-γ gene expression and hepatotoxic effect. Finally, it was recapitulated that these derivatives can provide a new prospect towards the development of antidiabetic agents with fewer side effects.
Asunto(s)
Benzotiazoles/uso terapéutico , Diabetes Mellitus Experimental/tratamiento farmacológico , Hipoglucemiantes/uso terapéutico , PPAR gamma/agonistas , Fenilpropionatos/uso terapéutico , Animales , Benzotiazoles/síntesis química , Benzotiazoles/metabolismo , Benzotiazoles/toxicidad , Peso Corporal/efectos de los fármacos , Diabetes Mellitus Experimental/patología , Diseño de Fármacos , Expresión Génica/efectos de los fármacos , Hipoglucemiantes/síntesis química , Hipoglucemiantes/metabolismo , Hipoglucemiantes/toxicidad , Hígado/patología , Masculino , Simulación del Acoplamiento Molecular , Estructura Molecular , PPAR gamma/metabolismo , Fenilpropionatos/síntesis química , Fenilpropionatos/metabolismo , Fenilpropionatos/toxicidad , Ratas Wistar , Relación Estructura-ActividadRESUMEN
A green chemistry approach has been developed for the synthesis of chromene dihydropyrimidinone (CDHPM) using recyclable Fe/Al pillared clay catalyst. Pharmacokinetic parameters like aqueous solubility, lipophilicity, P-glycoprotein (P-gp) ATPase activity, permeability, plasma protein binding, red blood cell (RBC) partitioning, metabolic stability in liver microsomes and in silico computations have been studied for the most potent anticancer chromene dihydropyrimidinone hybrid 1. This compound exhibited low solubility, optimum lipophilicity, no P-gp inhibitory activity, intermediate permeability, high plasma protein binding, low RBC partitioning, acceptable metabolic stability in rat liver microsomes (RLM) as well as human liver microsomes (HLM) with transitional hepatic extraction ratio.
Asunto(s)
Benzopiranos/síntesis química , Tecnología Química Verde/métodos , Benzopiranos/farmacocinética , Fenómenos Bioquímicos , HumanosRESUMEN
A library of nineteen benzoxazolinone-based 1,3,4-thiadiazoles has been synthesized and screened for their anti-inflammatory activity. The compound 1f exhibited a potent anti-inflammatory activity with an inhibition of 65.83% and 32.50% after 3 h and 5 h respectively. It also exhibited a significant in vitro (p < 0.01), TNF- α inhibitory activity with 51.44 % inhibition. The compound 1f showed hydrogen bonding with GLN 61 and interactions with TYR 119, TYR 151 and GLY 121. The histopathology report showed that none of the compounds caused gastric ulceration. The results from the in vivo & in vitro antiinflammatory activity along with In Silico studies exhibit that benzoxazolinone-based 1,3,4-thiadiazoles may be used in the future development of anti-inflammatory drugs.
RESUMEN
Recent findings of potential implications of glycogen synthase kinase-3ß (GSK-3ß) dysfunction in psychiatric disorders like depression, have increased focus for development of GSK-3ß inhibitors with possible anti-depressant activity. Keeping this in view, we synthesized a series of benzimidazole-linked-1,3,4-oxadiazole carboxamides and evaluated them for in vitro GSK-3ß inhibition. Active compounds were investigated for in vivo antidepressant activity in Wistar rats. Docking studies of active compounds have also been performed. Among nineteen compounds synthesized, compounds 7a, 7r, 7j, and 7d exhibited significant potency against GSK-3ß in sub-micromolar range with IC50 values of 0.13⯵M, 0.14⯵M, 0.20⯵M, 0.22⯵M respectively and significantly reduced immobility time (antidepressant-like activity) in rats compared to control group. Docking study showed key interactions of these compounds with GSK-3ß. These compounds may thus serve as valuable candidates for subsequent development of effective drugs against depression and related disorders.
Asunto(s)
Antidepresivos/farmacología , Depresión/tratamiento farmacológico , Glucógeno Sintasa Quinasa 3 beta/antagonistas & inhibidores , Oxadiazoles/farmacología , Animales , Antidepresivos/síntesis química , Antidepresivos/química , Conducta Animal/efectos de los fármacos , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Femenino , Glucógeno Sintasa Quinasa 3 beta/metabolismo , Suspensión Trasera , Humanos , Masculino , Simulación de Dinámica Molecular , Estructura Molecular , Oxadiazoles/síntesis química , Oxadiazoles/química , Ratas , Ratas Wistar , Proteínas Recombinantes/metabolismo , Relación Estructura-ActividadRESUMEN
Recent studies reveal that glycogen synthase kinase-3ß (GSK-3ß) acts as a pro-inflammatory enzyme, and by inhibiting this kinase, inflammation can be controlled. In this regard, a series of 17 piperazine-linked oxazolo[4,5-b]pyridine-based derivatives was synthesized and evaluated for in vitro GSK-3ß inhibitory and in vivo anti-inflammatory activity. The compounds 7d, 7e, 7g, and 7c displayed the best GSK-3ß inhibitory activity among all the synthesized compounds, with corresponding IC50 values of 0.34, 0.39, 0.47, and 0.53 µM. Among the compounds 7d, 7e, 7g, and 7c examined for in vivo anti-inflammatory activity in the rat paw edema model, compound 7d exhibited maximum inhibition, reducing the paw volume by 62.79 and 65.91% at 3 and 5 h post-carrageenan administration, respectively, in comparison to indomethacin (76.74% at 3 h and 79.54% at 5 h after carrageenan administration). Furthermore, these compounds (7d, 7e, 7g, and 7c) were also found to substantially inhibit pro-inflammatory mediators, i.e., TNF-α, IL-1ß, and IL-6, ex vivo in comparison to indomethacin and did not pose any gastric ulceration risk, indicating the potential of this oxazolopyridine scaffold for the development of GSK-3ß inhibitors and their application as anti-inflammatory agents.
Asunto(s)
Antiinflamatorios/farmacología , Glucógeno Sintasa Quinasa 3 beta/antagonistas & inhibidores , Inflamación/tratamiento farmacológico , Piperazinas/farmacología , Amidas/síntesis química , Amidas/química , Amidas/farmacología , Animales , Antiinflamatorios/síntesis química , Antiinflamatorios/química , Carragenina , Modelos Animales de Enfermedad , Edema/tratamiento farmacológico , Edema/patología , Femenino , Indometacina/farmacología , Inflamación/patología , Mediadores de Inflamación/metabolismo , Concentración 50 Inhibidora , Masculino , Piperazinas/síntesis química , Piperazinas/química , Piridinas/síntesis química , Piridinas/química , Piridinas/farmacología , Ratas , Ratas WistarRESUMEN
A library of fourteen 2-imino-4-thiazolidinone derivatives (1a-1n) has been synthesized and evaluated for in vivo anti-inflammatory activity and effect on ex-vivo COX-2 and TNF-α expression. Compounds 1k (5-(2,4-dichloro-phenooxy)-acetic acid (3-benzyl-4-oxo-thiazolidin-2-ylidene)-hydrazide) and 1m (5-(2,4-dichloro-phenooxy)-acetic acid (3-cyclohexyl-4-oxo-thiazolidin-2-ylidene)-hydrazide) exhibited in vivo inhibition of 81.14% and 78.80% respectively after 5h in comparison to indomethacin which showed 76.36% inhibition of inflammation without causing any damage to the stomach. Compound 1k showed a reduction of 68.32% in the level of COX-2 as compared to the indomethacin which exhibited 66.23% inhibition of COX-2. The selectivity index of compound 1k was found to be 29.00 in comparison to indomethacin showing selectivity index of 0.476. Compounds 1k and 1m were also found to significantly suppress TNF-α concentration to 70.10% and 68.43% in comparison to indomethacin which exhibited 66.45% suppression.
Asunto(s)
Ácido 2,4-Diclorofenoxiacético/química , Antiinflamatorios/farmacología , Tiazoles/farmacología , Animales , Antiinflamatorios/química , Diseño de Fármacos , Ratas , Ratas Wistar , Úlcera Gástrica/prevención & control , Relación Estructura-Actividad , Tiazoles/síntesis química , Tiazoles/química , Factor de Necrosis Tumoral alfa/metabolismoRESUMEN
GSK-3 specific inhibitors are promising candidates for the treatment of devastating pathologies such as diabetes, neurodegenerative diseases and cancers. We have synthesized a library of pyrimidin-4-one-1,2,3-triazole conjugates using click-chemistry approach and evaluated them as glycogen synthase kinase-3ß inhibitors. Compounds 3g, 3j, 3n and 3r were found to be most potent among the eighteen pyrimidin-4-one-1,2,3-triazole conjugates synthesized and they were further evaluated for their in vivo anti-depressant activity. Compound 3n (2-((1-(3,4-dimethylphenyl)-1H-1,2,3-triazol-4-yl)methylthio)-3-methyl-6-phenylpyrimidin-4(3H)-one) exhibited the most potent inhibitory activity against GSK-3ß with IC50 value of 82nM and was also found to exhibit significant antidepressant activity at 50mg/kg, when compared with fluoxetine, a known antidepressant drug. The molecular docking studies were performed to elucidate the binding modes of the compounds with the GSK-3ß target and two crucial interactions namely, hydrogen bond formation with Val 135 and Lys 183 residues in the active site of GSK-3ß were observed.
Asunto(s)
Antidepresivos/farmacología , Glucógeno Sintasa Quinasa 3 beta/antagonistas & inhibidores , Inhibidores de Proteínas Quinasas/farmacología , Pirimidinas/farmacología , Triazoles/farmacología , Antidepresivos/síntesis química , Antidepresivos/química , Cristalografía por Rayos X , Relación Dosis-Respuesta a Droga , Glucógeno Sintasa Quinasa 3 beta/metabolismo , Humanos , Modelos Moleculares , Estructura Molecular , Inhibidores de Proteínas Quinasas/síntesis química , Inhibidores de Proteínas Quinasas/química , Pirimidinas/síntesis química , Pirimidinas/química , Relación Estructura-Actividad , Triazoles/síntesis química , Triazoles/químicaRESUMEN
A series of benzimidazole based thiadiazole and carbohydrazide conjugates have been synthesized and evaluated for inhibition of glycogen synthase kinase-3ß and anti-depressant effect. Compounds 4f, 4j, 5b, 5g and 5i were found to be the most potent inhibitors of GSK-3ß in vitro amongst the twenty-five benzimidazole based thiadiazole and carbohydrazide conjugates synthesized. Compound 5i was also found to exhibit significant antidepressant activity in vivo at 50mg/kg, when compared to fluoxetine, a known antidepressant drug. The molecular docking studies revealed multiple hydrogen bond interactions by the synthesized compounds with various amino acid residues, viz, ASP-133, LYS-183, PRO-136, VAL-135, TYR-134, or LYS-60 at the GSK-3ß receptor site.
Asunto(s)
Antipsicóticos/síntesis química , Bencimidazoles/química , Glucógeno Sintasa Quinasa 3 beta/antagonistas & inhibidores , Animales , Antipsicóticos/química , Antipsicóticos/farmacología , Conducta Animal/efectos de los fármacos , Bencimidazoles/síntesis química , Bencimidazoles/farmacología , Sitios de Unión , Glucógeno Sintasa Quinasa 3 beta/metabolismo , Hidrazinas/química , Enlace de Hidrógeno , Aprendizaje por Laberinto/efectos de los fármacos , Ratones , Simulación del Acoplamiento Molecular , Estructura Terciaria de Proteína , Tiadiazoles/químicaRESUMEN
Piperine is an alkaloid responsible for the pungency of black pepper. In this study, piperine isolated from Piper nigrum L. was hydrolyzed under basic condition to obtain piperic acid and was used as precursor to carry out the synthesis of twenty piperine derivatives containing benzothiazole moiety. All the benzothiazole derivatives were evaluated for their antidiabetic potential by OGT test followed by assessment of active derivatives on STZ-induced diabetic model. It was observed that nine of twenty novel piperine analogues (5b, 6a-h), showed significantly higher antidiabetic activity in comparison with rosiglitazone (standard). Furthermore, these active derivatives were evaluated for their action as PPAR-γ agonists demonstrating their mechanism of action. The effects on body weight, lipid peroxidation, and hepatotoxicity after administration with active derivatives were also studied to further establish these derivatives as lead molecules for treatment of diabetes with lesser side-effects.
Asunto(s)
Diabetes Mellitus Experimental/tratamiento farmacológico , Hipoglucemiantes/química , Hipoglucemiantes/uso terapéutico , PPAR gamma/agonistas , Piperidinas/química , Piperidinas/uso terapéutico , Animales , Glucemia/análisis , Glucemia/metabolismo , Diabetes Mellitus Experimental/genética , Diabetes Mellitus Experimental/metabolismo , Regulación de la Expresión Génica/efectos de los fármacos , Células HEK293 , Humanos , Hipoglucemiantes/farmacología , Peroxidación de Lípido/efectos de los fármacos , Masculino , Simulación del Acoplamiento Molecular , PPAR gamma/genética , PPAR gamma/metabolismo , Piper nigrum/química , Piperidinas/farmacología , Ratas WistarRESUMEN
Twenty one pyrazoline containing benzenesulfonylureas were synthesized and docked against PPAR-γ target. All the compounds were first screened for their antidiabetic potential by oral glucose tolerance test and then six active compounds were assessed on STZ diabetic model. It was found that five compounds showed significantly high antidiabetic activity in comparison to glibenclamide as well as rosiglitazone (standard drugs). The active compounds were evaluated for their effect on body weight since weight management is one of the main concerns associated with sulfonylureas. Finally, the most active compound 6f was shown to elevate PPAR-γ gene expression. The synthesized compounds were also screened for anticancer activity by National Cancer Institute. Five compounds (5i, 6e, 6g, 6i and 6j) were selected at one dose level and showed potency against cancers.
Asunto(s)
Antineoplásicos/farmacología , Hipoglucemiantes/farmacología , PPAR gamma/agonistas , Compuestos de Sulfonilurea/farmacología , Animales , Antineoplásicos/síntesis química , Antineoplásicos/química , Proliferación Celular/efectos de los fármacos , Diabetes Mellitus Experimental/inducido químicamente , Diabetes Mellitus Experimental/tratamiento farmacológico , Relación Dosis-Respuesta a Droga , Ensayos de Selección de Medicamentos Antitumorales , Humanos , Hipoglucemiantes/síntesis química , Hipoglucemiantes/química , Modelos Moleculares , Estructura Molecular , PPAR gamma/genética , Pirazoles/química , Pirazoles/farmacología , Ratas , Ratas Wistar , Estreptozocina , Relación Estructura-Actividad , Compuestos de Sulfonilurea/síntesis química , Compuestos de Sulfonilurea/químicaRESUMEN
Alzheimer's disease is an age related disorder and is defined to be progressive, irreversible neurodegenerative disease. The potential targets which are associated with the Alzheimer's disease are cholinesterases, N-methyl-D-aspartate receptor, Beta secretase 1, Pregnane X receptor (PXR) and P-glycoprotein (Pgp). P-glycoprotein is a member of the ATP binding cassette (ABC) transporter family, which is an important integral of the blood-brain, blood-cerebrospinal fluid and the blood-testis barrier. Reports from the literature provide evidences that the up-regulation of the efflux pump is liable for a decrease in ß -amyloid intracellular accumulation and is an important hallmark in Alzheimer's disease (AD). Thus, targeting ß-amyloid clearance by stimulating Pgp could be a useful strategy to prevent Alzheimer's advancement. Currently available drugs provide limited effectiveness and do not assure to cure Alzheimer's disease completely. On the other hand, the current research is now directed towards the development of synthetic or natural based therapeutics which can delay the onset or progression of Alzheimer's disease. Since ancient time medicinal plants such as Withania somnifera, Bacopa monieri, Nerium indicum have been used to prevent neurological disorders including Alzheimer's disease. Till today around 125 Indian medicinal plants have been screened on the basis of ethnopharmacology for their activity against neurological disorders. In this paper, we report bioactives from natural sources which show binding affinity towards the Pgp receptor using ligand based pharmacophore development, virtual screening, molecular docking and molecular dynamics simulation studies for the bioactives possessing acceptable ADME properties. These bioactives can thus be useful to treat Alzheimer's disease.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/efectos de los fármacos , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Enfermedad de Alzheimer/tratamiento farmacológico , Enfermedad de Alzheimer/metabolismo , Péptidos beta-Amiloides/metabolismo , Productos Biológicos/farmacología , Simulación por Computador , Ensayos Analíticos de Alto Rendimiento , Humanos , Ligandos , Modelos Moleculares , Simulación del Acoplamiento Molecular , Simulación de Dinámica Molecular , Farmacogenética , Receptores de Droga/química , Receptores de Droga/efectos de los fármacosRESUMEN
A library of synthesized conjugates of phenoxy acetic acid and thiazolidinedione 5a-m showed potent peroxisome proliferator activated receptor-γ (PPAR-γ) transactivation as well as significant blood glucose lowering effect comparable to the standard drugs pioglitazone and rosiglitazone. Most of the compounds showed higher docking scores than the standard drug rosiglitazone in the molecular docking study. Compounds 5l and 5m exhibited PPAR-γ transactivation of 54.21 and 55.41%, respectively, in comparison to the standard drugs pioglitazone and rosiglitazone, which showed 65.94 and 82.21% activation, respectively. Compounds 5l and 5m significantly lowered the blood glucose level of STZ-induced diabetic rats. Compounds 5l and 5m lowered the AST, ALT, and ALP levels more than the standard drug pioglitazone. PPAR-γ gene expression was significantly increased by compound 5m (2.00-fold) in comparison to the standard drugs pioglitazone (1.5-fold) and rosiglitazone (1.0-fold). Compounds 5l and 5m did not cause any damage to the liver and could be considered as promising candidates for the development of new antidiabetic agents.
Asunto(s)
Glucemia/efectos de los fármacos , Diabetes Mellitus Experimental/tratamiento farmacológico , Diseño de Fármacos , Hipoglucemiantes/síntesis química , Hipoglucemiantes/farmacología , PPAR gamma/antagonistas & inhibidores , Tiazolidinedionas/síntesis química , Tiazolidinedionas/farmacología , Células 3T3-L1 , Animales , Sitios de Unión , Glucemia/metabolismo , Diabetes Mellitus Experimental/sangre , Femenino , Células HEK293 , Humanos , Hipoglucemiantes/metabolismo , Hipoglucemiantes/toxicidad , Ligandos , Hígado/efectos de los fármacos , Hígado/patología , Masculino , Ratones , Simulación del Acoplamiento Molecular , Estructura Molecular , PPAR gamma/genética , PPAR gamma/metabolismo , Pioglitazona , Unión Proteica , Ratas Wistar , Rosiglitazona , Relación Estructura-Actividad , Tiazolidinedionas/metabolismo , Tiazolidinedionas/toxicidad , TransfecciónRESUMEN
A series of substituted pyrazolines (2a-e, 3a-h and 6a-c) and isoxazolines (4a-e) were synthesized and their structures were established on the basis of IR, (1)H NMR, (13)C NMR and mass spectra. All the synthesized compounds were tested against two bacterial and four fungal strains and found to exhibit moderate to potent antifungal activity. Compounds 2b, 4c, 4d and 6a-c exhibited significant activity against all tested fungal strains. MIC values of all the active compounds were comparable with standard drug fluconazole. The results of the in silico molecular docking study supported the antifungal activity of the synthesized compounds.
Asunto(s)
Antibacterianos/síntesis química , Antibacterianos/farmacología , Antifúngicos/síntesis química , Antifúngicos/farmacología , Bacterias/efectos de los fármacos , Hongos/efectos de los fármacos , Bacterias/crecimiento & desarrollo , Sistema Enzimático del Citocromo P-450/química , Fluconazol/farmacología , Hongos/crecimiento & desarrollo , Isoxazoles/química , Espectroscopía de Resonancia Magnética , Pruebas de Sensibilidad Microbiana , Simulación del Acoplamiento Molecular , Pirazoles/química , Relación Estructura-ActividadRESUMEN
Nineteen novel piperine based triazoles have been synthesized using click chemistry approach and were tested for in vivo anti-inflammatory activity. The most active compounds were evaluated for in vitro TNF-α expression. Compounds 3g and 3f were found to show significant in vivo inhibition of inflammation, 80.40% and 76.71%, respectively after 5 h in comparison to piperine (54.72%) and the standard drug indomethacin (77.02%) without causing any damage to the stomach. Compounds 3g and 3f suppressed TNF-α level by 73.73% and 70.64%, respectively and protein expression of COX-2, NF-κB and TNF-α more than indomethacin. Moreover, the compound 3g was found to show significant analgesic activity of 54.09% which was comparable with the indomethacin (57.43%).
Asunto(s)
Analgésicos/farmacología , Antiinflamatorios no Esteroideos/farmacología , Antiulcerosos/farmacología , Ácidos Grasos Insaturados/farmacología , Úlcera Gástrica/tratamiento farmacológico , Triazoles/farmacología , Analgésicos/síntesis química , Analgésicos/química , Animales , Antiinflamatorios no Esteroideos/síntesis química , Antiinflamatorios no Esteroideos/química , Antiulcerosos/síntesis química , Antiulcerosos/química , Línea Celular , Supervivencia Celular/efectos de los fármacos , Química Clic , Relación Dosis-Respuesta a Droga , Diseño de Fármacos , Ácidos Grasos Insaturados/síntesis química , Ácidos Grasos Insaturados/química , Ratones , Modelos Moleculares , Estructura Molecular , Piper nigrum/química , Ratas , Ratas Wistar , Úlcera Gástrica/patología , Relación Estructura-Actividad , Triazoles/síntesis química , Triazoles/químicaRESUMEN
A focused library of novel benzyl pyrrolones has been synthesized and their in silico molecular docking studies carried out against TNF-α target. Among all the docked molecules, compound 3f showed best glide score of -6.89. All the synthesized compounds were evaluated for in vivo anti-inflammatory activity by carrageenan-induced paw edema model. Compounds showing significant anti-inflammatory activity were further tested for their in vitro TNF α expression. Compounds 3b and 2b were found to show significant inhibition of 76.22% and 71.47%, respectively after 5 h in comparison with standard drug indomethacin, which showed 80.98% inhibition of inflammation. Compounds 3b and 2b also suppressed TNF α level by 65.03% and 60.90% as compared indomethacin, which showed 68.84% of inhibition. Compound 3b showed significant analgesic activity of 60.04%, and its activity was comparable with indomethacin (64.04%). Compounds 3b and 2b were also tested for their effect on protein expression of COX-2 and NF-κB in the liver tissues. Compounds 3b and 2b were further evaluated for their gastric risk and lipid peroxidation action and showed superior GI safety along with reduction of LPO as compared to indomethacin. Hepatotoxicity study showed that these two compounds did not cause any damage to liver.
Asunto(s)
4-Butirolactona/análogos & derivados , Antiinflamatorios no Esteroideos/química , Antiinflamatorios no Esteroideos/farmacología , Factor de Necrosis Tumoral alfa/metabolismo , 4-Butirolactona/química , Animales , Antiinflamatorios no Esteroideos/síntesis química , Carragenina/toxicidad , Diseño de Fármacos , Evaluación Preclínica de Medicamentos/métodos , Femenino , Peroxidación de Lípido/efectos de los fármacos , Hígado/efectos de los fármacos , Masculino , Ratones , Simulación del Acoplamiento Molecular , Ratas , Úlcera Gástrica/tratamiento farmacológico , Relación Estructura-Actividad , Factor de Necrosis Tumoral alfa/químicaRESUMEN
In the present study a library of twenty six benzenesulfonylureas containing thiophenylpyrazoline moiety has been synthesized. All the compounds were docked against PPAR-γ target. Most of the compounds displayed higher dock score than standard drugs, glibenclamide and rosiglitazone. All the synthesized compounds were primarily evaluated for their antidiabetic effect by oral glucose tolerance test. Further assessment of antidiabetic potential of sixteen active compounds was then done on STZ induced diabetic model. The results of in vivo activity by both the methods were found to be consistent with each other as well as with docking studies. Change in body weight of STZ induced animals post treatment was also assessed at the end of study. In vitro PPAR-γ transactivation assay was performed on active compounds in order to validate docking results and the most active compound 3 k was also shown to elevate gene expression of PPAR-γ. Furthermore, the compounds were screened by National Cancer Institute, Bethesda for anticancer effect and two compounds 3h and 3 i were selected at one dose level since they exhibited sensitivity towards tumor cell lines (mainly melanoma).
Asunto(s)
Antineoplásicos/química , Hipoglucemiantes/química , Pirazoles/química , Compuestos de Sulfonilurea/química , Compuestos de Sulfonilurea/farmacología , Células 3T3-L1 , Animales , Antineoplásicos/síntesis química , Antineoplásicos/farmacología , Sitios de Unión , Dominio Catalítico , Línea Celular , Proliferación Celular/efectos de los fármacos , Diabetes Mellitus Experimental/inducido químicamente , Diabetes Mellitus Experimental/tratamiento farmacológico , Ensayos de Selección de Medicamentos Antitumorales , Prueba de Tolerancia a la Glucosa , Hipoglucemiantes/farmacología , Hipoglucemiantes/uso terapéutico , Ratones , Simulación del Acoplamiento Molecular , PPAR gamma/química , PPAR gamma/metabolismo , Ratas , Ratas Wistar , Relación Estructura-ActividadRESUMEN
The present study aims at the synthesis of pyrazolines bearing benzothiazole and their evaluation as anti-inflammatory agents. The synthesized compounds were evaluated for their anti-inflammatory potential using carrageenan induced paw edema model. Two compounds 5a and 5d alleviated inflammation more than the standard drug celecoxib. Eight compounds 5 b, 5 c, 5 e, 5 g, 5 h, 6 b, 6 e and 6 f showed anti-inflammatory activity comparable to celecoxib. To understand the mode of action, COX-2 enzyme assay and TNF-α assay were carried out. All the active compounds were assessed for their cytotoxicity. The ulcerogenic risk evaluation was performed on the active compounds that were not found to be cytotoxic. Out of ten active compounds, two compounds (5 d and 6 f) were finally found to be the most potent anti-inflammatory agents attributing to the suppression of the COX-2 enzyme activity and TNF-α production without being either cytotoxic or ulcerogenic.